Meet the Experts Transporter Conference San Francisco 2017
As a pioneer in the drug transporter field for 16 years, SOLVO is dedicated to exploring the science of transporters and their role in xenobiotic efficacy and safety. With frequent Webinars hosted by respected scholars and professionals, as well as numerous peer-reviewed publications, our commitment and scientific contribution to the transporter field is well recognized.
After the great success of our events in SOLVO’s Meet the Experts: Transporter Conference series, we are pleased to announce that the sixth event will be held in San Francisco on 10-12 April, 2017. With the Meet the Experts: Transporter Conference series, we took our commitment to the transporter field to a new level. The sessions will focusing on the most relevant and up-to-date aspects of transporter science and industry applications.
Venue: Embassy Suites San Francisco Airport: 250 Gateway Boulevard, South San Francisco, California, 94080, USA
BENET, Leslie Z., PhD
BiographyDr. Benet, Professor and former Chairman (1978-1998), Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California, San Francisco, received his A.B. (English), B.S. (Pharmacy), M.S. from the University of Michigan and Ph.D. from the University of California. He has received nine honorary doctorates. His research interests, more than 550 publications, 6 books and 12 patents are in the areas of pharmacokinetics, biopharmaceutics, drug delivery and pharmacodynamics. Dr. Benet is listed by Thompson Reuters as one of the most highly cited pharmacologists worldwide, with his published peer-reviewed papers cited more than 24,000 times. His recent work on the interplay of metabolic enzymes and transport proteins as related to oral bioavailability led to development of the Biopharmaceutics Drug Disposition Classification System (BDDCS). Dr. Benet was a Founder and first President of the American Association of Pharmaceutical Scientists (AAPS). Dr. Benet is an elected member of the National Academy of Medicine (formerly IOM) of the U.S. National Academy of Sciences and a member of the International Transporter Consortium.
BROUWER, Kim, PharmD, PhD
BiographyDr. Brouwer is Associate Dean for Research and Graduate Education, UNC Eshelman School of Pharmacy, and Kenan Distinguished Professor in the School of Pharmacy and Curriculum in Toxicology at UNC-Chapel Hill. She received her BS in Pharmacy from Oregon State University, PharmD/Residency training and a PhD in Pharmaceutical Sciences/Pharmacokinetics from the University of Kentucky (UK) College of Pharmacy, and postdoctoral training in Pharmacology/Drug Metabolism in the UK College of Medicine prior to joining the UNC faculty. Dr. Brouwer directs an NIH-funded research program focused on hepatobiliary drug disposition, hepatic transport proteins, and development/refinement of in vitro models to predict in vivo hepatic drug disposition, drug interactions, and hepatotoxicity. Dr. Brouwer was founding Director of the UNC Pharmacokinetics/Pharmacodynamics Fellowship Program and is Co-PI of an NIH-funded Postdoctoral T32 Training Program in Clinical Pharmacology. She has mentored 40 clinical pharmacology fellows, 25 postdoctoral fellows/visiting scholars, 34 doctoral students, 23 undergraduate/honors students, and published >200 research papers, reviews and book chapters. Dr. Brouwer is co-inventor of B-CLEAR®, an in vitro method to assess hepatobiliary disposition that correlates with in vivo data, and is co-founder of Qualyst Transporter Solutions, a UNC spin-off company. She is a member of the International Transporter Consortium Steering Committee, the ASCPT Board of Directors, and she is a member of the following editorial advisory boards: Clinical Pharmacology and Therapeutics, CPT Pharmacometrics & Systems Pharmacology, Clinical and Translational Science, and the AAPS Journal. She served as a member of the NIH Pharmacology Study Section (1998-2002), the NIH Quantitative and Systems Pharmacology Working Group (2010-2012), and co-Chair of the NICHD Pediatric Transporters Working Group (2012-2015). Dr. Brouwer was recognized as an AAPS Fellow in 1998 and received the 2001 PhRMA Foundation Award in Excellence in Pharmaceutics. In 2009, Dr. Brouwer was named a Kenan Distinguished Professor, one of the highest honors bestowed on UNC faculty.
CHEMUTURI, Nagendra, PhD
BiographyNagendra Chemuturi received his Bachelor Degree in Pharmacy with Distinction from Kakatiya University in India. He then worked as a pharmaceutical salesman before pursuing his Ph.D. at the University of Iowa. He was awarded the AAPS Graduate Symposium Award in 2005 for his dissertation work on the role of nasal drug transporters and metabolism in preferential nose-to-brain uptake of dopamine into brain. He started his career in the US at Vertex Pharmaceuticals in MA in 2005. Since then, he has worked at Alcon-Novartis and is currently a Principal Pharmacokineticist with Seattle Genetics characterizing ADME of ADCs. During his career he has served as DMPK lead on several small and large molecule projects and has led efforts to understand the role of drug transporters in ophthalmology and ADCs. He has given podium presentations at several scientific conferences, is active in IQ consortium, leading the MABEL working group and has authored/co-authored several articles and book chapters.
EL-KATTAN, Ayman, PhD
BiographyDr. Ayman El-Kattan is Associate Research Fellow at the Pharmacokinetics, Dynamics, and Metabolism Department, Pfizer Inc. Cambridge Laboratories. He earned his bachelor degree in pharmacy with distinction from University of Jordan and a Ph.D. in Basic Pharmaceutical Sciences at University of South Carolina in the US. His main research interests are focused on understanding the role of transporters in influencing drug disposition and oral absorption. Also, it involves studying the utility of physiological based pharmacokinetic modeling (PBPK) tools in projecting drug disposition and drug-drug interaction liabilities in man for new molecular entities (NME). He is also an Adjunct Professor at College of Pharmacy-University of Rhode Island in Rhode Island, US where he lectures in the graduate-level pharmacokinetic courses and serves as external advisor on dissertation committees. Dr. El-Kattan is a reviewer for several journals and is an active member of the American Association of Pharmaceutical Scientists (AAPS) and serves on the executive committee of the Drug Transporter focus group. He has been invited speaker over 50 times at national and international conferences and meetings and has published over 100 papers in peer-reviewed Journals, book chapters and proceedings.
HARIPARSAD, Niresh, PhD
BiographyDr. Niresh Hariparsad, PhD is a Director, at Vertex Pharmaceuticals Inc. Dr. Hariparsad received his B. Pharm. and MMed Sc (Clin Pharm) degrees from the University of Kwazulu-Natal in South Africa. Dr Hariparsad received his PhD from the University of Cincinnati and worked as a Senior Research Chemist in the Drug Metabolism and Pharmacokinetics Department at Merck and Co. before joining Vertex in 2010. His research interests include the use of novel tools to predict drug-drug interaction risk in the clinic.
KRAJCSI Péter, PhD
Chief Scientific Officer, SOLVO Biotechnology Budaors, Hungary
Dr. Peter Krajcsi has extensive experience in biotechnology. He received his PhD in biochemistry from University of Szeged and later a Doctor of Sciences degree in biological sciences from the Hungarian Academy of Sciences. In his academic career he has focused on three major topics (i) steroid receptors (ii) molecular biology of adenoviruses and (iii) apoptosis. For the past 13 years he has been working in R&D management positions for small and medium size enterprises in drug research and gene therapy in Hungary as well as in the United States. Since 2002 he is the Chief Scientific Officer of Solvo Biotechnology. At Solvo the focus is on membrane transporters and utilization of membrane transporter technology in drug discovery and development as well as in development of diagnostics tools for cancer and inflammatory diseases.